Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sodium Glucose Cotransporter-2 Inhibitor DAPAgliflozin Versus Thiazide Diuretic in Patients With Heart Failure and Diuretic RESISTance: a Multi-centre, Open-label, Randomised Controlled Clinical Trial

NCT04860011 is registered in ClinicalTrials.gov with NHS Greater Glasgow and Clyde as lead sponsor.

NCT NCT04860011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04860011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sodium Glucose Cotransporter-2 Inhibitor DAPAgliflozin Versus Thiazide Diuretic in Patients With Heart Failure and Diuretic RESISTance: a Multi-centre, Open-label, Randomised Controlled Clinical Trial
Lead sponsor
NHS Greater Glasgow and Clyde
Phase
Phase 3
Overall status
Unknown status
Start date
April 27, 2021
Completion date
April 3, 2023
Enrollment
61 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure